Clinical implications of p53: Effect on prognosis, tumor progression and chemotherapy response

Seminars in Cancer Biology

Volumn 8, Issue 5, 1998, Pages 379-387

  Peller, Shoshana ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; Carcinogenesis; Drug resistance; p53 mutation; p53 tumor suppressor gene

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CARCINOGENESIS; HUMAN; PROGNOSIS; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0031987285     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1998.0100     Document Type: Article

References (95)

1. 1. Lane D (1992) p53, guardian of the genome. Nature 358:15-16
2. 2. Lane D, Crawford LV (1979) T antigens bound to a host protein in SV40 transformed cells. Nature 278:261-263
3. 3. Linzer DIH, Levine AJ (1979) Characterization of a 54000 MW cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52
4. 4. Soussi T, Caron de Fromental C, May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952
5. 5. El-Deiry WS, Kern SE, Pietenpol JA, Kinzlier KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nature Genet 1:45-49
6. 6. Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455
7. 7. Fields S, Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1048
8. 8. Jeffrey PD, Gorina S, Pavletich NP (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267:1498-1502
9. 9. Shaulsky G, Goldfinger N, Benzeev A, Rotter V (1990) Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 10:6565-6577
10. 10. Reed M, Woelker B, Wang P, Wang Y, Anderson ME, Tegtmeyer P (1995) The c-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci USA 92:9455-9459
11. 11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311
12. 12. Stewart N, Hicks GG, Paraskevas F, Mowat M (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109-115
13. 13. Schwartz D, Almog N, Peled A, Goldfinger N, Rotter V (1997) Role of wild type p53 in the G2 phase: regulation of the γ-irradiation induced delay and DNA repair. Oncogene 15:2597-2607
14. 14. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345-347
15. 15. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355
16. 16. Soussi T, May P (1996) Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol 260:623-637
17. 17. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R (1997) Database of p53 somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acid Res 25:151-157
18. 18. Harris CC (1996) The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumor-suppressor gene. Br J Cancer 73:261-269
19. 19. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B (1994) Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57:1-9
20. 20. Thor AD, Moore DH, Edgerton SM et al (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855
21. 21. Borresen A-L, Andersen TI, Eyfjord JE, Cornelis RS, Thoracius S et al (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Gene Chromos Cancer 14:71-75
22. 22. Jervall P, Makinen M, Kattunen T, Makela J, Vihko P (1997) Conserved region mutations of the p53 gene are concentrated in distal colorectal cancers. Int J Cancer 74:97-101
23. 23. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K (1997) K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 75:1125-1130
24. 24. Roy-Burman P, Zheng J, Miller GJ (1997) Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis? Mol Med Today 476-482
25. 25. Gumerlock PH, Chi S-G, Shi X-B, Voeller HJ, Jacobson JW, Gelman EP, White RW, DeVere (1997) p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. J Natl Cancer Inst 89:66-71
26. 26. Shuyer M, HenzelLogmans SC, vqanderBurg MEL, Fieret EJH, Kijin JGM, Foekens JA, Berns EMJJ (1998) High prevalence of codon 213 (arg → stop) mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands. Int J Cancer 76:299-303
27. 27. Prokocimer M, Rotter V (1994) Structure and function of p53 in normal cells and their abberations in cancer cells: projection on the hematologic cell lineage. Blood 84:2391-2411
28. 28. Preudhomme C, Fenaux P (1997) The clinical significance of mutations of the p53 tumor suppressor gene in haematological malignancies. Br J Haematol 98:502-511
29. 29. Ichkawa A, Kinoshita T, Watanabe T et al (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529-534
30. 30. Peller S, Yona R, Kopilova Y, Prokocimer M et al (1998) Molecular alteration in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Gene Chrom Cancer 21:2-7
31. 31. Moll UM, Riou G, Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: mutations and nuclear exclusion. Proc Natl Acad Sci USA 89:7262-7266
32. 32. Barnes DM, Hanby AM, Gillett CE et al (1992) Abnormal expression of wild type p53 in normal cells of a cancer family patient. Lancet 340:259-263
33. 33. Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT, Olsfield EH (1994) Heterogeneity of subcellular localization of p53 protein in human glioblastomas. Cancer Res 54:1-5
34. 34. Moll UM, LaGuaglia MB, Riou G (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastoma but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407-4411
35. 35. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AKC (1994) Cytoplasmic accumulation of p53 protein, an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86:681-687
36. 36. Schlamp CL, Poulsen GL, Nork TM, Nickells RW (1997) Nuclear exclusion of wild-type p53 immortalized human retinoblastoma cells. J Natl Cancer Inst 89:1530-1536
37. 37. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G (1996) Cytoplasmic sequestration of wild-type p53 protein impairs the G1 check point after DNA damage. Mol Cell Biol 16:1126-1137
38. 38. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, LopezBernstein G, Lozano G, Sarkiss M, McDonnell TJ (1997) Bcl-2 inhibits nuclear import following DNA damage. Oncogene 15:2767-2772
39. 39. Takada S, Kaneniwa N, Tsuchida N, Koike K (1997) Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 15:1895-1901
40. 40. Elmore LW, Hancock AR, Chang SF et al (1997) Hepatitis B virus X 1 protein and tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 94:14707-14712
41. 41. Momand J, Zambetti GP, Olson DC, Goerge D, Levine AJ (1992) The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237-1245
42. 42. El-Deiry WS, Tokino T, Velulesco VE, Levy DB, Parsons R, Trent JM et al (1993) WAF1 a potential mediator of p53 tumor suppression. Cell 73:817-825
43. 43. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299
44. 44. Chresta CM, Hickman JA (1996) Oddball p53 in testicular tumors. Nature Med 2:745-746
45. 45. Lutzker SG, Levine AJ (1996) A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med 2:804-810
46. 46. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V (1986) The molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650-4656
47. 47. Murata M, Tagawa M, Kimura H, Watanabe S, Saiaho H (1996) Analysis of a germ line polymorphism of the p53 gene in lung cancer patients, discrete results with smoking history. Carcinogenesis 17:261-264
48. 48. Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rotter V (1995) A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol 14:983-990
49. 49. Storey A, Thomas M, Kalita A, Harwood C et al (1998) Role of a p53 polymorphism in the human papilloma-virus-associated cancer. Nature 393:229-234
50. 50. Strauss BS (1997) Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Carcinogenesis 18:1445-1452
51. 51. Soussi T (1996) The humoral response to the tumor suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today 17:354-356
52. 52. Collet B, Raoul JL, LeBerre N, Hersbach D, Meritte H, Quillien V, DeCertaines JD (1997) Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus: comparison with p53 alterations and lymph node invasion. Inter J Oncol 11:617-621
53. 53. Malkin D, Li FP, Strong LC, Fraumeni JFJ et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238
54. 54. Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101-124
55. 55. Varley JM, Evans Dgr, Birch JM (1997) Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer 76:1-14
56. 56. Barel D, Avigad S, Mor C, Fogel M, Cohen IJ, Zaizov R (1998) A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family. Cancer Genet Cytogenet 103:1-6
57. 57. Frebourg T, Friend SH (1992) Cancer risks from germline p53 mutations. J Clin Invest 90:1637-1641
58. 58. Felix CA, D'Amico D, Mitsudomi T et al (1992) Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. J Clin Invest 96:653-658
59. 59. Prosser J, Elder PA, Condie A, MacFadyen I, Steel CM, Evans HJ (1991) Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br J Cancer 63:181-184
60. 60. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
61. 61. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767
62. 62. Kahlenberg MS, Stoler DL, Basik M, Petrelli NJ, Rodrigues-Bigas M, Anderson GR (1996) p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers. J Natl Cancer Inst 88:1665-1670
63. 63. Kinzler KW, Vogelstein B (1996) Life (and death) in a malignant tumour. Nature 379:19-20
64. 64. Fanklin WA, Gazdar AF, Haney J et al (1997) Widely dispersed p53 mutation in respiratory epithelium. J Clin Invest 100:2133-2137
65. 65. Kishimoto Y, Shiota G, Kamisaki Y et al (1997) Loss of the tumor suppressor p53 gene at the liver cirrhosis stage in Japanese patients with hepatocellular carcinoma. Oncology 54:304-310
66. 66. Coursen JD, Bennet WP, Khan MA, Forrester K, Pietenpol JA, Harris CC (1997) Differential effects of p53 mutations on the growth of human bronchial epithelial cells. Mol Carcinogen 19:191-203
67. 67. Williams AC, Miller JC, Collard T, Browne SJ, Newbold RF, Paraskeva C (1997) The effect of different TP53 mutations on the chromosomal stability of a human colonie adenoma derived cell line with endogenous wild type TP53 activity, before and after DNA damage. Gene Chromos Cancer 20:44-52
68. 68. Watanabe M, Fukutome K, Shiraishi T et al (1997) Differences in the p53 gene mutational spectra of prostate cancers between Japan and Western countries. Carcinogenesis 18:1355-1358
69. 69. Wynford-Thomas D, Blaydes J (1998) The influence of cell context on the selection pressure for p53 mutation in human cancer. Carcinogenesis 19:29-36
70. 70. Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967
71. 71. Kastan MB, Canman CE, Leonard CY (1995) p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 14:3-15
72. 72. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389:300-305
73. 73. Kastan M (1997) On the TRAIL from p53 to apoptosis? Nature Genet 17:130-131
74. 74. Barlow C, Brown KD, Deng C-X, Tagle DA, Wynshaw-Boris A (1997) Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nature Genet 17:453-456
75. 75. Lowe SW, Bodis S, McClatchey A et al (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810
76. 76. Shelling AN (1997) Role of p53 in drug resistance in ovarian cancer. Lancet 349:744-745
77. 77. Hamada M, Fujiwara T, Hizuta A et al (1996) The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 122:360-365
78. 78. Elledge RM, Gray R, Mansour E et al (1995) Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256
79. 79. Berns EMJJ, Klijn JGM, van Putten WLJ et al (1998) p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Invest 16:121-127
80. 80. Aas T, Borresen A-L, Geisler S et al (1996) Specific p53 mutations are associated with de novo resistance to doxorubicine in breast cancer patients. Nature Med 2:811-814
81. 81. Silvestrini R, Veneroni S, Benini E et al (1997) Expression of p53, glutathione S-transferase-II, and bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89:639-645
82. 82. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y (1998) Selective sensitivity to radiation of cerebral gioblastomas harboring p53 mutations. Cancer Res 58:1793-1797
83. 83. Christodoulopoulos G, Fotouhi N, Krajewski S, Reed JC, Alaoui-Jamali M, Panasci L (1997) Relationship between nitrogen mustard drug resistance in B-CLL and protein expression of bcl-2, bax, bcl-x and p53. Cancer Lett 121:59-67
84. 84. Wlodarski P, Wasik M, Ratajczak MZ et al (1998) Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood 91:2998-3006
85. 85. Liu M, Pelling JC, Chu E, Brash DE (1998) Antioxidant action via p53-mediated apoptosis. Cancer Res 58:1723-1729
86. 86. Leri A, Claudio PP, Li Q et al (1998) Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the bcl-2-to-bax protein ratio in the cell. J Clin Invest 101:1326-1342
87. 87. Blagosklonny MV, ElDeiry WS (1998) Acute expression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75:933-940
88. 88. Ogawa N, Fujiwara T, Kagwa S et al (1997) Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 73:367-370
89. 89. Zeng YX, Prabhu NS, ElDeiry WS (1997) Adenovirus-mediated p53 gene therapy in nasopharyngeal cancer. Int J Oncol 11:221-226
90. 90. Roth JA, Nguyen D, Lawrence DD et al (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 2:985-991
91. 91. Selivanova G, Iotsova V, Okan I et al (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the c-terminal domain. Nature Med 3:632-638
92. 92. Wieczorek AM, Waterman JLF, Waterman MJF, Halazonetis TD (1996) Structure-based rescue of common tumor-derived p53 mutants. Nature Med 2:1143-1146
93. 93. Gnjatic S, Gai Z, Viguier M, Chouabi S, Guillet J-G, Choppin J (1998) Accumulation of the p53 protein allows recognition by human CTL of wild type p53 epitope presented by breast carcinomas and melanomas. J Immunol 160:328-333
94. 94. Kapoor M, Lozano G (1998) Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci USA 95:2834-2837
95. 95. Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-phosphorylation of p53 alleviates inhibition by mdm2. Cell 91:325-334